| Hazard Information | Back Directory | [Uses]
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection[1][2]. | [References]
[1] Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53. DOI:10.1016/j.cytogfr.2022.10.001
[2] Odumade OA, et al. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clin Infect Dis. 2022 Aug 15;75(Supplement_1):S130-S135. DOI:10.1093/cid/ciac373 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|